OS Therapies Reports Positive Phase 2b Biomarker Data for OST-HER2 in Osteosarcoma Trial
I'm PortAI, I can summarize articles.
OS Therapies Inc. reported positive biomarker data from its Phase 2b trial of OST-HER2 for treating pulmonary metastatic osteosarcoma. The data showed that immune blood biomarkers in the interferon gamma pathway can distinguish long-term survivors from short-term ones. The company is preparing submissions for regulatory approval in the UK, US, and Europe, targeting 2026. OST-HER2 has received multiple designations from the FDA and EMA, including Orphan Disease and Fast Track Designations.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments